1. Home
  2. SEVN vs SGMT Comparison

SEVN vs SGMT Comparison

Compare SEVN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seven Hills Realty Trust

SEVN

Seven Hills Realty Trust

HOLD

Current Price

$7.57

Market Cap

174.0M

Sector

Real Estate

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$10.84

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEVN
SGMT
Founded
1986
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
174.0M
169.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
SEVN
SGMT
Price
$7.57
$10.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$10.50
$26.13
AVG Volume (30 Days)
120.6K
1.2M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
13.90%
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$29,383,000.00
$2,000,000.00
Revenue This Year
$27.75
N/A
Revenue Next Year
$4.06
N/A
P/E Ratio
$39.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.37
$4.50
52 Week High
$11.15
$11.24

Technical Indicators

Market Signals
Indicator
SEVN
SGMT
Relative Strength Index (RSI) 41.18 65.22
Support Level $7.41 $6.60
Resistance Level $7.84 $11.15
Average True Range (ATR) 0.12 0.51
MACD 0.00 -0.03
Stochastic Oscillator 26.37 70.54

Price Performance

Historical Comparison
SEVN
SGMT

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: